Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.

PsoriasisPsoriatic Arthritis

The risk of treated anxiety and treated depression among patients with psoriasis and PsA treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database

J Eur Acad Dermatol Venereol.

Vasilakis-Scaramozza C, Persson R, Hagberg KW, Jick S

doi: 10.1111/jdv.16231.

Psoriasis

The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and post-marketing surveillance data

Br J Dermatol

Lebwohl M, Deodhar A, Griffiths CEM, Menter MA, Poddubnyy D, Bao W, Jehl V, Marfo K, Primatesta P, Shete A, Trivedi V, Mease PJ

doi: 10.1111/bjd.20136

Psoriasis

Incidence of Psoriatic Arthritis in Patients with Skin Psoriasis and Associated Risk Factors: A Retrospective Population-based Cohort Study in Swedish Routine Clinical Care

Acta Derm Venereol

Lindberg I, Lilja M, Geale K, Tian H, Richardson C, Scott A, Osmancevic A

doi: 10.2340/00015555-3682

Psoriasis

The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort study

J Am Acad Dermatol.

Wu JJ, Sundaram M, Cloutier M, Gauthier-Loiselle M, Guérin A, Singh R, Ganguli A

doi: 10.1016/

Psoriasis

Psoriasis Flares Following Systemic Glucocorticoid Exposure in Patients With a History of Psoriasis

JAMA Dermatol

Gregoire ARF, DeRuyter BK, Stratman EJ

doi: 10.1001/jamadermatol.2020.4219

Psoriasis

Association of Patient Mental Health Status With the Level of Agreement Between Patient and Physician Ratings of Psoriasis Severity

JAMA Dermatol

Carr E, Mahil SK, Brailean A, Dasandi T, Pink AE, Barker JN, Rayner L, Turner MA, Goldsmith K, Smith CH

doi: 10.1001/jamadermatol.2020.5844

Psoriasis

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)

J Am Acad Dermatol.

Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A

doi: 10.1016/j.jaad.2017.08.051.

Psoriasis

Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis

JAMA Dermatol.

Dommasch ED, Kim SC, Lee MP, Gagne JJ

doi: 10.1001/jamadermatol.

Psoriasis

Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: The PROSE study population

J Eur Acad Dermatol Venereol.

Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Rissler M, Gathmann S, Sieder C, Baeumer D, Orsenigo R

doi: 10.1111/jdv.16400.

Related content

The risk of treated anxiety and treated depression among patients with psoriasis and PsA treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database

The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and post-marketing surveillance data

Incidence of Psoriatic Arthritis in Patients with Skin Psoriasis and Associated Risk Factors: A Retrospective Population-based Cohort Study in Swedish Routine Clinical Care

The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort study

Psoriasis Flares Following Systemic Glucocorticoid Exposure in Patients With a History of Psoriasis

Association of Patient Mental Health Status With the Level of Agreement Between Patient and Physician Ratings of Psoriasis Severity

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis

Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: The PROSE study population